Watson Pharmaceuticals
This article was originally published in The Tan Sheet
Executive Summary
Introducing nicotine polacrilex gum in 2 mg and 4 mg strengths this summer following FDA approval of the products March 15 and March 19, respectively. The delay of the launch reflects the company's need for time to position its first OTC product, Watson says. The reference drug is SmithKline Beecham's Nicorette, which lost Waxman/Hatch marketing exclusivity Feb. 9 ("The Tan Sheet" Jan. 18, p. 4)